Back to Search Start Over

Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide.

Authors :
Fukuda, Masamichi
Takeda, Nobuo
Ishida, Hidetoshi
Seki, Yusuke
Shibata, Naoko
Takahashi, Nobuo
Sugiyama, Kazuhisa
Kubo, Eri
Sasaki, Hiroshi
Source :
Journal of Ocular Pharmacology & Therapeutics; Jan/Feb2022, Vol. 38 Issue 1, p85-91, 7p
Publication Year :
2022

Abstract

Purpose: We assessed the effect of rebamipide ophthalmic solution on corneal epithelial injury due to benzalkonium chloride (BAK) by fluorescein (FL) staining and corneal resistance (CR). Methods: After determining the absence of corneal epithelial damage by FL and CR, rebamipide ophthalmic solution (50 μL) was instilled five times, each interspaced by 5 min, into one eye of mature New Zealand white rabbits, and likewise physiological saline was instilled into the contralateral eye as the control. After 30 min, eyes were similarly treated with one of the following solutions: BAK solution 0.02%, latanoprost ophthalmic solution (0.02% BAK), or latanoprost ophthalmic solution without BAK. The presence of corneal epithelial damage was quantitated at 10, 30, and 60 min by CR after the last instillation. FL staining was also performed at 60 min after the last instillation. Results: CR ratios (%) at 60 min after the last instillation in rebamipide/BAK and rebamipide/latanoprost (0.02% BAK) groups were significantly increased by 18.3% and 25.6% compared with saline/BAK and saline/latanoprost (0.02% BAK) groups, respectively (P < 0.05). Findings by FL staining were consistent with those by CR; BAK and latanoprost with BAK groups were positive, and eyes with the most severe area and density of corneal epithelial damage (A2D2) were in the saline/BAK group. Conclusion: The rebamipide ophthalmic solution reduces the severity of corneal epithelial injury caused by BAK, an ophthalmic solution preservative. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10807683
Volume :
38
Issue :
1
Database :
Complementary Index
Journal :
Journal of Ocular Pharmacology & Therapeutics
Publication Type :
Academic Journal
Accession number :
154926380
Full Text :
https://doi.org/10.1089/jop.2021.0052